Resources Repository
-
ArticlePublication 2017Distributional Benefits of Tobacco Tax and Smoke-Free Workplaces in China
This study used the extended cost–effectiveness analysis (ECEA) to evaluate, across income quintiles of the …
This study used the extended cost–effectiveness analysis (ECEA) to evaluate, across income quintiles of the male population, the premature deaths averted, the change in tax revenues generated, and the financial risk protection procured, that would follow a 75% increase in cigarette prices through substantial increments in excise tax fully passed onto consumers, and a nationwide total implementation of workplace smoking bans. A 75% increase in cigarette prices would avert about 24 million premature deaths among…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Chronic Disease/Risk | Social Determinants | Policy/Regulation | Asia & Pacific -
ArticlePublication 2015Consequences of Tobacco Tax in Rich and Poor Smokers in China: An ECEA
This study used the extended cost-effectiveness analysis methods to estimate, across income quintiles of the …
This study used the extended cost-effectiveness analysis methods to estimate, across income quintiles of the male population, the health benefits (years of life gained), the additional tax revenues raised, the net financial consequences for households, and the financial risk protection provided to households, that would be caused by a 50% increase in tobacco price through excise tax fully passed onto tobacco consumers in China. The analysis showed that a 50% increase in tobacco price through…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Chronic Disease/Risk | Social Determinants | Policy/Regulation | Asia & Pacific -
ArticlePublication 2019Health and Financial Benefits of Averting Malaria in Zambia: An ECEA
This study used the extended cost-effectiveness analysis (ECEA) to examine impact of the hypothetical rollout …
This study used the extended cost-effectiveness analysis (ECEA) to examine impact of the hypothetical rollout of the malaria vaccine RTS,S/AS01 in Zambia on the health benefits of children under five, and financial benefits on their households. The authors assumed a three-dose vaccination schedule (over 6-9 months), and vaccine cost of US$5 per dose. To assess vaccine impact, for each income quintile, they computed the number of under-five malaria deaths prevented, the household out-of-pocket (OOP) malaria-related…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Infectious Diseases | Health Systems | Sub-Saharan Africa -
ArticlePublication 2018Poverty Reduction & Equity Benefits of Measles, Rotavirus and Pneumococcal Vaccines in LMICs
This study uses the extended cost effectiveness analysis (ECEA) to evaluate the impact of immunization …
This study uses the extended cost effectiveness analysis (ECEA) to evaluate the impact of immunization against measles, severe pneumococcal disease and severe rotavirus for birth cohorts vaccinated over 2016–2030 for three scenarios in 41 Gavi-eligible countries: no immunization, current immunization coverage forecasts and the current immunization coverage enhanced with funding support. Following the distribution of the cases by socioeconomic group, the study found that the number of catastrophic health costs (CHC) cases attributable to measles,…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Infectious Diseases | Child/Nutrition | Global -
ArticlePublication 2019Impact of a Tax on Sweetened Beverages in the Philippines: an ECEA
This study used extended cost-effectiveness analyses to estimate the effect of the sweetened beverages tax …
This study used extended cost-effectiveness analyses to estimate the effect of the sweetened beverages tax in the Philippines on the numbers of premature deaths averted attributed to type 2 diabetes mellitus, ischemic heart disease and stroke, across income quintiles over the period 2018-2037. The study also estimated the financial benefits of the tax from reductions in out-of-pocket payments, direct medical costs averted, and government health-care cost savings. The analysis showed that the tax could avert…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Child/Nutrition | Chronic Disease/Risk | Social Determinants | Policy/Regulation | Asia & Pacific -
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Chronic Disease/Risk | Global -
ArticlePublication 2019Cost-Effectiveness of Clinic, Home, or Ambulatory Blood Pressure Measurement for Hypertension Diagnosis
This study compared three methods of blood pressure (BP) measurement for diagnosing hypertension in primary …
This study compared three methods of blood pressure (BP) measurement for diagnosing hypertension in primary care settings, accounting for the possibility of false-positive (white-coat hypertension) and false-negative (masked hypertension) clinic measurements. Outcomes included quality-adjusted life years (QALYs) and lifetime costs associated with clinic BP measurement, home BP monitoring, and ambulatory blood pressure monitoring (ABPM) under two scenarios: positive and negative initial screening. Data were from published literature, public data sources, and expert input. In the…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Clinical Care | North America -
ArticlePublication 2019Cost-Effectiveness of Latent TB Screening before Immigration to Low-Incidence Countries
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening …
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening for active infections, screening for latent TB infection before immigration is rare. The authors used discrete event simulation to evaluate the cost-effectiveness preimmigration latent TB infection screening for migrants to low-incidence countries. They calculated cost per quality-adjusted life-year gained for migrants from countries with different TB incidences. Their analysis when combined with research on sustainability, acceptability, and program implementation can…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Dynamic Simulation | Infectious Diseases | Government/Law | Global -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Policy/Regulation | Global